drugset / Trial / NCT05469750

Dalpiciclib Plus Letrozole and Capecitabine

NCT05469750

Phase 2 Unknown 48 enrolled Fujian Medical University Union Hospital
NaSingle-groupOpen-labelTreatment

Summary

to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer

Timeline

Start
2022-08-10
Primary completion
2023-08
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Dalpiciclib Small molecule 150 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications